| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(17 years from now) | |
Multrys is owned by Am Regent.
Multrys contains Cupric Sulfate; Manganese Sulfate; Selenious Acid; Zinc Sulfate.
Multrys has a total of 1 drug patent out of which 0 drug patents have expired.
Multrys was authorised for market use on 30 June, 2021.
Multrys is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Multrys from 01 May, 2023.
The generics of Multrys are possible to be released after 01 July, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
MULTRYS family patents
